PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
August 10, 2026DrugsOpen Access

Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShrey SindhwaniMTMiles ThomasKGKanika Gehlaut

Discussion

Loading...

Member takes

Overview

Review assesses biology and emerging therapeutics in small-cell lung cancer, indicating potential for improved management.

Key Points

  • This review aims to provide a comprehensive overview of the biology and treatment advancements in small-cell lung cancer (SCLC).
  • Discusses multidisciplinary management of SCLC stages.
  • Analyzes recent FDA-approved therapies and ongoing clinical trials.
  • Examines the molecular landscape and its impact on treatment strategies.
  • FDA approval of tarlatamab offers unprecedented survival advantage in SCLC.
  • Emerging therapies aim to improve outcomes in both first-line and later-line settings.
  • A significant shift in standards of care is anticipated with novel therapeutic strategies.

Cite This Study

Sindhwani et al. (2026) studied this question.

synapsesocial.com/papers/6a797ce09c20a9bbd3183fffhttps://doi.org/10.1007/s40265-026-02353-7
View Full Paper
Ask AI
Bookmark
Share